Sun Pharmaceutical Industries has launched Unloxcyt in the United States following FDA approval of an updated label, expanding treatment options for patients with advanced cutaneous squamous cell carcinoma.
Max Healthcare has collaborated with Google to allow patients to book hospital appointments directly from Google Search and Maps, making access to verified care faster, simpler, and more reliable across India.
Boehringer Ingelheim has initiated a phase IIa clinical trial to evaluate BI 765423, a monoclonal antibody targeting interleukin-11 (IL-11), for the treatment of idiopathic pulmonary fibrosis (IPF). The study is part of the company’s ongoing resea...
As health-tech startups and pharmaceutical innovators drive rapid adoption of injectable weight-loss drugs, new UK research has raised questions about their durability as long-term obesity solutions. While medications such as semaglutide (Wegovy...
Biocon Pharma, a subsidiary of Biocon Ltd, has received approval from the United States Food and Drug Administration (US FDA) for its generic everolimus tablets for oral suspension. The approval was granted under an Abbreviated New Drug Applicatio...
Eli Lilly and Company announced today a major partnership with NVIDIA to launch a first-of-its-kind AI co-innovation lab designed to take on some of the pharmaceutical industry’s hardest problems. The collaboration will see the two companies...
AbbVie and RemeGen have entered into an exclusive global licensing agreement to develop and commercialise RC148, an investigational bispecific antibody for cancer treatment. Under the agreement, AbbVie will hold rights to RC148 outside Greater Ch...
.jpeg)
Aragen launches CHOMax, a cell line and early manufacturing platform, taking monoclonal antibody programmes from DNA to IND-enabling clinical supply in 10 months.
.png)
Lupin Limited has signed an exclusive license, supply, and distribution agreement to commercialize Bofanglutide in India, marking a major step in the battle against type 2 diabetes and obesity. Under the pact with China’s Gan&Lee Pharmaceuticals...
Merck & Co. has initiated KANDLELIT-007, a global Phase 3 clinical trial evaluating its investigational oral KRAS G12C inhibitor calderasib (MK-1084) in combination with KEYTRUDA QLEX™, a subcutaneous formulation of pembrolizumab with berahyalur...
.jpg)
, CDSCO.jpg)